UCT-03008 is under clinical development by 1200 Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how UCT-03008’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GlobalData
Report-cover

Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - UCT-03008 in Solid Tumor

Buy the Report

Related Company Profiles

View all

UCT-03008 overview

UCT-03008 is under development for the treatment of advanced solid tumor. It is administered through oral route. The drug candidate is a kinase inhibitor.

1200 Pharma overview

1200 Pharma, is a developer of novel oncology therapeutics utilizing breakthrough medicinal chemistry. The company is headquartered in United States.

For a complete picture of UCT-03008’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.